Ahammune Biosciences Secures $5 Million in Series A Funding to Advance Vitiligo Drug Development
- September 25, 2024
Ahammune Biosciences, an innovative biotech firm focused on dermatological therapies, has successfully raised $5 million in a Series A funding round led by the early-stage venture capital firm pi Ventures. This funding
